ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Safety Study of Fondaparinux Sodium to Prevent Venous Thromboembolic Events (APOLLO)

This study has been completed.

Sponsors and Collaborators: Sanofi-Aventis
Organon
Information provided by: Sanofi-Aventis
ClinicalTrials.gov Identifier: NCT00038961
  Purpose

This study is a randomized, double-blind, deep vein thrombosis (DVT) prevention trial in patients undergoing major abdominal surgery in 80 U.S. centers. All patients receive background treatment of intermittent pneumatic compression devices. All subjects are assessed for DVTs with bilateral venography at the end of the study drug treatment period (day 5-9).


Condition Intervention Phase
Venous Thrombosis
Drug: Fondaparinux Sodium
Phase III

MedlinePlus related topics:   Deep Vein Thrombosis   

Drug Information available for:   Fondaparinux sodium    ORG 31540   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Multicenter, Randomized, Double-Blind, Parallel Group Trial to Demonstrate the Efficacy of Fondaparinux Sodium in Association With Intermittent Pneumatic Compression Versus Intermittent Pneumatic Compression Used Alone for the Prevention of Venous Thromboembolic Events in Patients at Increased Risk Undergoing Major Abdominal Surgery

Further study details as provided by Sanofi-Aventis:

Estimated Enrollment:   1070
Study Start Date:   October 2001
Estimated Study Completion Date:   July 2004
Primary Completion Date:   July 2004 (Final data collection date for primary outcome measure)

  Eligibility
Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria
  • Undergoing abdominal surgery (any surgery between the diaphragm and pelvic floor) lasting longer than 45 minutes (duration from anesthesia induction to surgical closure)
  • Over 40 years of age
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00038961

Show 31 study locations  Show 31 Study Locations

Sponsors and Collaborators
Sanofi-Aventis
Organon
  More Information


Related Info  This link exits the ClinicalTrials.gov site
 

Responsible Party:   sanofi-aventis ( ICD Study Director )
Study ID Numbers:   EFC3558, SR90107A, ARIXTRA, ORG31540
First Received:   June 5, 2002
Last Updated:   April 25, 2008
ClinicalTrials.gov Identifier:   NCT00038961
Health Authority:   United States: Food and Drug Administration

Keywords provided by Sanofi-Aventis:
DVT Prevention  
Major Abdominal Surgery  
Venous Thromboembolic  

Study placed in the following topic categories:
Embolism and Thrombosis
Embolism
Vascular Diseases
Fondaparinux
Venous Thrombosis
Org 31540
Thrombosis

Additional relevant MeSH terms:
Fibrin Modulating Agents
Anticoagulants
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Hematologic Agents
Fibrinolytic Agents
Cardiovascular Diseases
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on November 20, 2008




Links to all studies - primarily for crawlers